BEAM / Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates

Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have more_horizontal

Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and C more_horizontal

Beam recently announced a reorganization that involves layoffs and a narrowing of its pipeline. The company lost $82.8 million in the second quarter. more_horizontal

Beam Therapeutics is progressing well with its phase 1/2 BEACON study using BEAM-101 for severe sickle cell disease treatment; Data expected in 2024. more_horizontal

Pre-revenue biotechs like Beam Therapeutics bring plenty of risk. The good news is that it has plenty of money and some help from Pfizer, too. more_horizontal

BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its wo more_horizontal

Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructurin more_horizontal

Beam Therapeutics Inc. BEAM, -6.60% said Thursday it will reduce headcount by 100 employees, or about 20% of its workforce, to help it extend its cash more_horizontal